Literature DB >> 21993151

Ligustrazine derivatives. Part 5: design, synthesis and biological evaluation of novel ligustrazinyloxy-cinnamic acid derivatives as potent cardiovascular agents.

Hongfei Chen1, Guoning Li, Peng Zhan, Xinyong Liu.   

Abstract

A series of novel ligustrazinyloxy-cinnamic acid derivatives were designed, synthesized and evaluated for their inhibitory effect on adenosine diphosphate (ADP)-induced platelet aggregation in vitro, and also assayed for their protective effect against hydrogen peroxide (H(2)O(2))-induced oxidative damage on ECV-304 cells. Some compounds exhibited high activity in one or both of the assays, of which, compound 2e displayed the highest protective effect on the proliferation of the damaged ECV-304 cells (EC(50) = 0.020 mM), and compound 2f was the most active anti-platelet aggregation agent (EC(50) = 0.054 mM). Structure-activity relationships were briefly discussed.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21993151     DOI: 10.1016/j.ejmech.2011.09.030

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  6 in total

1.  Design, synthesis and evaluation of new ligustrazine derivatives as potential plasma-stable neuroprotective agents.

Authors:  Chenze Zhang; Wenqiang Yan; Rui Zhao; Bing Xu; Xiong Fang; Mengmeng Yan; Yuzhong Zhang; Penglong Wang; Haimin Lei
Journal:  Medchemcomm       Date:  2017-02-09       Impact factor: 3.597

2.  Ligustrazine reverts anthracycline chemotherapy resistance of human breast cancer by inhibiting JAK2/STAT3 signaling and decreasing fibrinogen gamma chain (FGG) expression.

Authors:  Yu-Lin Liu; Ze-Xuan Yan; Yu Xia; Xiao-Ye Xie; Kai Zhou; Li-Li Xu; Yan-Long Shi; Qiang Wang; Jing-Wang Bi
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

3.  Ligustrazinyl amides: a novel class of ligustrazine-phenolic acid derivatives with neuroprotective effects.

Authors:  Guoliang Li; Xin Xu; Kuo Xu; Fuhao Chu; Jixiang Song; Shen Zhou; Bing Xu; Yan Gong; Huazheng Zhang; Yuzhong Zhang; Penglong Wang; Haimin Lei
Journal:  Chem Cent J       Date:  2015-03-04       Impact factor: 4.215

4.  Ligustrazine Attenuates Myocardial Injury Induced by Coronary Microembolization in Rats by Activating the PI3K/Akt Pathway.

Authors:  Qiang Su; Xiangwei Lv; Ziliang Ye
Journal:  Oxid Med Cell Longev       Date:  2019-05-02       Impact factor: 6.543

Review 5.  Type 2 Diabetes Complicated With Heart Failure: Research on Therapeutic Mechanism and Potential Drug Development Based on Insulin Signaling Pathway.

Authors:  Hui Ye; Yanan He; Chuan Zheng; Fang Wang; Ming Yang; Junzhi Lin; Runchun Xu; Dingkun Zhang
Journal:  Front Pharmacol       Date:  2022-03-03       Impact factor: 5.810

6.  Qing-Xin-Jie-Yu Granules in addition to conventional treatment for patients with stable coronary artery disease (QUEST Trial): study protocol for a randomized controlled trial.

Authors:  Shengyao Li; Ming Guo; Huimin Mao; Zhuye Gao; Hao Xu; Dazhuo Shi
Journal:  Trials       Date:  2016-09-15       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.